Positions

Overview

  • I have a longstanding interest in the cause and clinical expression of IgA nephropathy. Research collaboration with colleagues over my career has focused on the genetically determined influences on the pathogenesis and the autoimmune nature of the mechanisms of disease. These studies have shown that there are many regions in the human genome that affect the risk for development of IgA nephropathy. We have also proposed a four-hit hypothesis for the pathogenesis: galactose-deficient IgA1 is recognized by IgG or IgA that binds to its galactose-deficient hinge-region glycans to form circulating immune complexes, some of which deposit in the mesangium of glomeruli to induce injury. Subsequent studies from centers around the world have supported this hypothesis. This model now serves as the blueprint for testing new approaches to therapy that are more disease-specific.
    I also am a transplant nephrologist. The kidney transplant program at UAB is one of the busiest in the USA. I have a special interest in outcomes and co-morbidities, including changes in bone mineral metabolism, post-transplant erythrocytosis, and genetic influences on long-term survival.

    • Selected Publications

    Academic Article

    Year Title Altmetric
    2020 APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO): Design and Rationale 2020
    2020 Role of Epstein-Barr Virus in Pathogenesis and Racial Distribution of IgA Nephropathy 2020
    2020 TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6–mediated pathways in IgA nephropathy 2020
    2020 Genome-wide association study for time to failure of kidney transplants from African American deceased donors 2020
    2020 Redefining the Influence of Ethnicity on Simultaneous Kidney and Pancreas Transplantation Outcomes: A 15-year Single-center Experience 2020
    2019 Autoantibodies Specific for Galactose-Deficient IgA1 in IgA Vasculitis With Nephritis 2019
    2019 Health-related quality of life in glomerular disease 2019
    2019 CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease 2019
    2019 Glomerular immunodeposits of patients with IgA nephropathy are enriched for IgG autoantibodies specific for galactose-deficient IgA1 2019
    2019 The emerging role of complement proteins as a target for therapy of IgA nephropathy 2019
    2018 Population Health, Ethnicity, and Rate of Living Donor Kidney Transplantation 2018
    2018 Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study 2018
    2018 Secondary IgA nephropathy 2018
    2018 Aberrant Glycosylation of the IgA1 Molecule in IgA Nephropathy 2018
    2018 Genome-wide association studies suggest that APOL1-environment interactions more likely trigger kidney disease in African Americans with nondiabetic nephropathy than strong APOL1–second gene interactions 2018
    2018 Assay for galactose-deficient IgA1 enables mechanistic studies with primary cells from IgA nephropathy patients 2018
    2018 Apolipoprotein L1 and Chronic Kidney Disease Risk in Young Potential Living Kidney Donors 2018
    2018 Evaluation of potential living kidney donors in the APOL1 era 2018
    2018 Life Expectancy for Patients From the Southeastern United States With IgA Nephropathy 2018
    2018 Serum galactose-deficient-IgA1 and IgG autoantibodies correlate in patients with IgA nephropathy 2018
    2017 Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis 2017
    2017 Apolipoprotein L1 Gene Effects on Kidney Transplantation 2017
    2017 Influence of Kidney Transplant Status on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage 2017
    2017 Effect of Replacing Race With Apolipoprotein L1 Genotype in Calculation of Kidney Donor Risk Index 2017
    2017 Prognostic value of serum biomarkers of autoimmunity for recurrence of IGA nephropathy after kidney transplantation 2017
    2017 A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction 2017
    2017 GWAS for serum galactose-deficient IgA1 implicates critical genes of the O-glycosylation pathway 2017
    2017 Evidence from the Oxford Classification cohort supports the clinical value of subclassification of focal segmental glomerulosclerosis in IgA nephropathy 2017
    2017 Inhibition of STAT3 Signaling Reduces IgA1 Autoantigen Production in IgA Nephropathy 2017
    2017 Serial Galactose-Deficient IgA1 Levels in Children with IgA Nephropathy and Healthy Controls 2017
    2016 The origin and activities of IgA1-containing immune complexes in IGA nephropathy 2016
    2016 Deceased-donor apolipoprotein L1 renal-risk variants have minimal effects on liver transplant outcomes 2016
    2016 APOL1 genotype and kidney transplantation outcomes from deceased african American donors 2016
    2016 Galactose-Deficient IgA1 as a Candidate Urinary Polypeptide Marker of IgA Nephropathy? 2016
    2016 Somatic mutations modulate autoantibodies against galactose-deficient IgA1 in IgA nephropathy 2016
    2016 The MEST score provides earlier risk prediction in lgA nephropathy 2016
    2016 Toward Noninvasive Diagnosis of IgA Nephropathy: A Pilot Urinary Metabolomic and Proteomic Study 2016
    2015 Deceased donor multidrug resistance protein 1 and caveolin 1 gene variants may influence allograft survival in kidney transplantation 2015
    2015 New Insights into the Pathogenesis of IgA Nephropathy. 2015
    2015 Should kidney donors be genotyped for APOL1 risk alleles? 2015
    2015 Apolipoprotein L1 gene variants in deceased organ donors are associated with renal allograft failure 2015
    2015 Current understanding of the role of complement in IgA nephropathy 2015
    2015 N-Acetylgalactosaminide α2,6-sialyltransferase II is a candidate enzyme for sialylation of galactose-deficient IgA1, the key autoantigen in IgA nephropathy 2015
    2014 Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens 2014
    2014 Cellular Signaling and Production of Galactose-Deficient IgA1 in IgA Nephropathy, an Autoimmune Disease 2014
    2014 Enzymatic sialylation of IgA1 O-glycans: Implications for studies of IgA nephropathy 2014
    2014 A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases 2014
    2014 Immune profile of IgA-dominant diffuse proliferative glomerulonephritis 2014
    2014 Cytokines alter IgA1 O-glycosylation by dysregulating C1GalT1 and ST6GalNAc-II enzymes 2014
    2014 End-stage renal disease in African Americans with lupus nephritis is associated with APOL1 2014
    2013 Biomarkers in IgA nephropathy: Relationship to pathogenetic hits 2013
    2013 Pathogenesis of immunoglobulin A nephropathy 2013
    2013 IgA nephropathy: Molecular mechanisms of the disease 2013
    2013 MEdical progress: IgA nephropathy 2013
    2012 The IgA1 immune complex-mediated activation of the MAPK/ERK kinase pathway in mesangial cells is associated with glomerular damage in IgA nephropathy 2012
    2012 Association of IgG co-deposition with serum levels of galactose-deficient IgA1 in pediatric IgA nephropathy. 2012
    2012 In vitro-generated immune complexes containing galactose-deficient IgA1 stimulate proliferation of mesangial cells 2012
    2012 Serum galactose-deficient IgA1 level is not associated with proteinuria in children with IgA nephropathy 2012
    2012 Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy 2012
    2012 Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis 2012
    2012 Reply to "genetic determinants of mycophenolate-related anemia and leukopenia after transplantation" 2012
    2012 Glycosylation of IgA1 and pathogenesis of IgA nephropathy 2012
    2012 Naturally occurring structural isomers in serum IgA1 O -glycosylation 2012
    2012 Association of IgG co-deposition with serum levels of galactose-deficient IgA1 in pediatric IgA nephropathy 2012
    2012 Erratum: Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy (Journal of Clinical Investigation (2011) 121, 10 (3991-4002) DOI: 10.1172/JCI45563) 2012
    2011 Membrane-assisted online renaturation for automated microfluidic lectin blotting 2011
    2011 Sugars and alcohol: IgA-associated renal diseases in alcoholic cirrhosis 2011
    2011 APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy 2011
    2011 IgA1 immune complexes from pediatric patients with IgA nephropathy activate cultured human mesangial cells 2011
    2011 Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy 2011
    2011 The pathophysiology of IgA nephropathy 2011
    2011 Aberrant glycosylation of iga1 and anti-glycan antibodies in iga nephropathy: Role of mucosal immune system 2011
    2011 Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathy 2011
    2011 Validation of the Oxford classification of IgA nephropathy 2011
    2011 Genetic determinants of mycophenolate-related anemia and leukopenia after transplantation 2011
    2011 Novel polymorphisms associated with tacrolimus trough concentrations: Results from a multicenter kidney transplant consortium 2011
    2011 Genome-wide association study identifies susceptibility loci for IgA nephropathy 2011
    2011 Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch-Schönlein purpura nephritis 2011
    2010 Clustered O-glycans of IgA1: Defining macro- and microheterogeneity by use of electron capture/transfer dissociation 2010
    2010 Galactose-deficient IgA1 in African Americans with IgA nephropathy: Serum levels and heritability 2010
    2010 Genetic studies of IgA nephropathy: Past, present, and future 2010
    2010 Recommendations for biomarker identification and qualification in clinical proteomics 2010
    2010 Recognition of galactose-deficient O-glycans in the hinge region of IgA1 by N-acetylgalactosamine-specific snail lectins: A comparative binding study. 2010
    2010 Glomerulonephritis after hematopoietic cell transplantation: IgA nephropathy with increased excretion of galactose-deficient IgA1 2010
    2010 Tissue distribution and biological activities of immune complexes are determined by their size and composition 2010
    2010 Familial IgA nephropathy in southeastern Kentucky. 2010
    2010 Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease 2010
    2010 The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults 2010
    2009 Application of proteomic analysis to renal disease in the clinic 2009
    2009 Sources of urinary proteins and their analysis by urinary proteomics for the detection of biomarkers of disease 2009
    2009 Risk factors and impact of recurrent lupus nephritis in patients with systemic lupus erythematosus undergoing renal transplantation: Data from a single US institution 2009
    2009 The Oxford classification of IgA nephropathy: Pathology definitions, correlations, and reproducibility 2009
    2009 The Oxford classification of IgA nephropathy: Rationale, clinicopathological correlations, and classification 2009
    2009 Secondary listing for deceased-donor kidney transplantation does not increase likelihood of engraftment at a large transplant center: Brief communication 2009
    2009 Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity 2009
    2009 Isolated central nervous system posttransplant lymphoproliferative disorder treated with high-dose intravenous methotrexate 2009
    2008 CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics 2008
    2008 Urinary proteomics in diabetes and CKD 2008
    2008 Systolic dysfunction portends increased mortality among those waiting for renal transplant 2008
    2008 Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy 2008
    2008 IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1 2008
    2008 Role of aberrant glycosylation of IgA1 molecules in the pathogenesis of iga nephropathy 2008
    2008 IgA Glycosylation and IgA Immune Complexes in the Pathogenesis of IgA Nephropathy 2008
    2007 Electrophoretic methods for analysis of urinary polypeptides in lgA-associated renal diseases 2007
    2007 Serum levels of galactose-deficient IgA in children with IgA nephropathy and Henoch-Schönlein purpura 2007
    2007 Analysis of O-glycan heterogeneity in IgA1 myeloma proteins by Fourier transform ion cyclotron resonance mass spectrometry: Implications for IgA nephropathy 2007
    2007 Urinary biomarkers of IgA nephropathy and other IgA-associated renal diseases 2007
    2007 High-resolution proteome/peptidome analysis of peptides and low-molecular-weight proteins in urine 2007
    2007 Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels 2007
    2007 The genetics of IgA nephropathy 2007
    2007 IgA nephropathy and henoch-schoenlein purpura nephritis: Aberrant glycosylation of IgA1, formation of IgA1-containing immune complexes, and activation of mesangial cells 2007
    2007 IgA nephropathy: A clinical overview 2007
    2007 IgA nephropathy: Characterization of IgG antibodies specific for galactose-deficient IgA1 2007
    2007 IgA nephropathy: Current views of immune complex formation 2007
    2007 Identification and Characterization of CMP-NeuAc:GalNAc-IgA1 α2,6-Sialyltransferase in IgA1-producing Cells 2007
    2007 Reactivities of N-acetylgalactosamine-specific lectins with human IgA1 proteins 2007
    2007 Clinical proteomics: A need to define the field and to begin to set adequate standards 2007
    2006 IgA-containing immune complexes in the urine of IgA nephropathy patients 2006
    2006 Brief communication: Glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation 2006
    2006 Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group. 2006
    2005 Recurrent IgA nephropathy after renal transplantation despite immunosuppressive regimens with mycophenolate mofetil 2005
    2005 IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells 2005
    2004 IgA nephropathy: An update 2004
    2004 Angiotensin II Receptor Type 1 Expression in Erythroid Progenitors: Implications for the Pathogenesis of Postrenal Transplant Erythrocytosis 2004
    2004 Incidence of hip osteonecrosis among renal transplantation recipients: A prospective study 2004
    2003 Bone mineral density changes within six months of renal transplantation. 2003
    2002 Interactions of human mesangial cells with IgA and IgA-containing immune complexes 2002
    2001 Progress in molecular and genetic studies of IgA nephropathy 2001
    2001 Tolerance in renal transplantation after allogeneic bone marrow transplantation-6-year follow-up 2001
    2000 IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23 2000
    2000 Treatment of IgA nephropathy 2000
    2000 Posttransplant lymphoproliferative disorder localized near the allograft in renal transplantation 2000
    2000 Focal posttransplantation lymphoproliferative disorder at the renal allograft hilum 2000
    2000 IgA1 glycosylation and the pathogenesis of IgA nephropathy 2000
    1999 Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: A phase II trial 1999
    1999 Expression of stem cell factor by osteoblasts in normal and hyperparathyroid bone: Relation to ectopic mast cell differentiation 1999
    1999 Parathyroid hormone-regulated production of stem cell factor in human osteoblasts and osteoblast-like cells 1999
    1999 Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies 1999
    1999 Progress in the pathogenesis of IgA nephropathy. 1999
    1999 Treatment of immunoglobulin A nephropathy 1999
    1998 Losartan, an Angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis 1998
    1998 Epidemiology of IgA nephropathy in central and eastern Kentucky for the period 1975 through 1994 1998
    1998 Late expression of tumor necrosis factor-α is markedly depressed in patients with IgA nephropathy 1998
    1997 Renal transplantation in African-American recipients: three decades at a single center. 1997
    1997 Angiotensin II stimulates proliferation of normal early erythroid progenitors 1997
    1997 Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG 1997
    1997 Human peritoneal B-1 cells and the influence of continuous ambulatory peritoneal dialysis on peritoneal and peripheral blood mononuclear cell (PBMC) composition and immunoglobulin levels 1997
    1997 The impact of renal transplantation on survival in hepatitis C- positive end-stage renal disease patients 1997
    1996 Amlodipine increases cyclosporine levels in hypertensive renal transplant patients: Results of a prospective study 1996
    1996 Impact of donor/recipient size matching on outcomes in renal transplantation 1996
    1996 Angiotensin converting enzyme gene polymorphism: Potential silencer motif and impact on progression in IgA nephropathy 1996
    1996 Benefits of continued cyclosporine through an indigent drug program 1996
    1996 Dilemmas in renal transplantation: When the clinical course and histological findings differ 1996
    1996 IgA nephropathy: Defect of glycosylation of IgA1 molecules 1996
    1995 Complications of the musculoskeletal system in renal transplant recipients 1995
    1995 IgA nephropathy: A disease of incomplete IgA 1 glycosylation? 1995
    1995 Intraperitoneal administration of tetanus toxoid elicits a specific responses of antibody-secreting cells in the peritoneal cavity 1995
    1995 Progress in Renal Transplantation a Single Center Study of 3359 Patients over 25 Years 1995
    1994 Hemolytically inactive C4B complement allotype caused by a proline to leucine mutation in the C5-binding site 1994
    1994 Erythropoiesis after withdrawal of enalapril in post-transplant erythrocytosis 1994
    1994 Immunological studies of IgA nephropathy in blacks reveal elevations of serum IgA2 as well as IgA1 1994
    1994 Intraperitoneal immunization of human subjects with tetanus toxoid induces specific antibody-secreting cells in the peritoneal cavity and in the circulation, but fails to elicit a secretory IgA response 1994
    1994 Posttransplant Erythrocytosis: An Enigma Revisited 1994
    1994 Renal retransplantation: The role of race, quadruple immunosuppression, and the flow cytometry cross-match 1994
    1993 Captopril-induced fall in glomerular filtration rate in cyclosporine-treated hypertensive patients 1993
    1993 Alternate-day prednisone therapy in IgA nephropathy. Preliminary analysis of a prospective, randomized, controlled trial. 1993
    1993 Bone loss after organ transplantation 1993
    1993 Defective galactosylation and clearance of IgA1 molecules as a possible etiopathogenic factor in IgA nephropathy. 1993
    1993 Experience with mycophenolate mofetil (RS61443) in renal transplantation at a single center 1993
    1993 Immunoglobulin A-Fibronectin Aggregate Levels in Children and Adults With Immunoglobulin A Nephropathy 1993
    1993 Metabolic bone disease in renal transplant recipients 1993
    1993 Reply 1993
    1993 Shared idiotypes in mesangial deposits in IgA nephropathy are not disease-specific 1993
    1993 Tapering or Discontinuing Cyclosporine for Financial Reasons—A Single-Center Experience 1993
    1992 Benefits of quadruple immunosuppressive therapy in recipients of living related donor kidneys: A review of 855 operations 1992
    1992 Binding of serum immunoglobulins to collagens in IgA nephropathy and HIV infection 1992
    1992 Cytokine-Induced Immunoglobulin Production in Primary IgA Nephropathy 1992
    1992 Familial IgA Nephropathy Associated With Bilateral Sensorineural Deafness 1992
    1992 IgA-containing immune complexes after challenge with food antigens in patients with IgA nephropathy 1992
    1992 Improved survival of primary cadaveric renal allografts in blacks with quadruple immunosuppression 1992
    1992 Musculoskeletal Complications After Renal Transplantation: Pathogenesis and Treatment 1992
    1992 Reply 1992
    1992 The impact of the UNOS mandatory sharing policy on recipients of the black and white races-experience at a single renal transplant center 1992
    1991 Rapid loss of vertebral mineral density after renal transplantation 1991
    1991 Are black living-related renal donors at greater long-term risk of renal complications than white donors? 1991
    1991 Analysis of 22 years experience in living-related transplantation at the University of Alabama in Birmingham. 1991
    1991 C4A deficiency and poor prognosis in patients with IgA nephropathy 1991
    1991 Effects of enalapril on erythrocytosis after renal transplantation 1991
    1991 Epstein-Barr virus Transformation of B Lymphocytes From IgA Nephropathy Patients and First-Degree Relatives Results in Increased Immunoglobulin Synthesis not Restricted to IgA 1991
    1991 IgA nephropathy in blacks: Studies of IgA2 allotypes and clinical course 1991
    1991 Long-term results of a controlled prospective study with transfusion of donor-specific bone marrow in 57 cadaveric renal allograft recipients 1991
    1991 Macroscopic Hematuria and Proteinuria Preceding Renal IgA Deposition in Patients With IgA Nephropathy 1991
    1991 OKT3 first-dose reaction: Association with T cell subsets and cytokine release 1991
    1991 Role for specific complement phenotypes and deficiencies in the clinical expression of IgA nephropathy 1991
    1991 Selective Elevation of Monomeric IgA1 in IgA Nephropathy Patients With Normal Renal Function 1991
    1990 C4B Deficiency in Two Siblings With IgA Nephropathy 1990
    1990 Cyclosporine-induced changes in glomerular filtration rate and urea excretion 1990
    1990 Cyclosporine-induced changes in glomerular filtration rate and urea excretion 1990
    1990 Donor antigen-specific immunosuppression in cadaveric and living-related donor kidney allograft recipients. 1990
    1990 J chain disease: A novel form of plasma cell dyscrasia 1990
    1990 Regional variation in C4 phenotype in patients with IgA nephropathy 1990
    1989 NON-SPECIFIC MESANGIAL STAINING WITH ANTIBODIES AGAINST CYTOMEGALOVIRUS IN IMMUNOGLOBULIN-A NEPHROPATHY 1989
    1989 Non-specific mesangial staining with antibodies against cytomegalovirus in immunoglobulin-A nephropathy 1989
    1989 Successful renal allografts in recipients with a positive standard, DTE negative cross-match 1989
    1989 Successful renal allografts in recipients with crossmatch-positive, dithioerythritol-treated negative sera: Race, transplant history, and HLA-DR1 phenotype 1989
    1989 Sustained high panel reactive antibody levels in highly sensitized patients: Significance of continued transfusions 1989
    1989 Use of cryopreserved donor bone marrow in cadaver kidney allograft recipients 1989
    1988 A Comparison of OKT3 Monoclonal Antibody and Corticosteroids in the Treatment of Acute Renal Allograft Rejection 1988
    1988 Activation of Complement in IgA Nephropathy 1988
    1988 Bilateral Cavernous Sinus Thrombosis due to Mucormycosis 1988
    1988 Early graft loss in cyclosporine A-treated cadaveric renal allograft recipients receiving retransplants against previous mismatched HLA-A, -B, -DR donor antigens 1988
    1988 Familial Clustering and Immunogenetic Aspects of IgA Nephropathy 1988
    1988 IgA nephropathy, the most common glomerulonephritis worldwide. A neglected disease in the United States? 1988
    1988 On the mechanism by which chloride corrects metabolic alkalosis in man 1988
    1987 Genetic factors in primary IgA nephropathy 1987
    1987 Morphologic and immunohistochemical observations in granulomatous glomerulonephritis 1987
    1987 A major gene model for the familial aggregation of plasma IgA concentration 1987
    1987 Aberrant synthesis of antibodies directed at the Fab fragment of IgA in patients with IgA nephropathies 1987
    1987 Analysis of immunoglobulin heavy chain restriction fragment length polymorphisms in IgA nephropathy. 1987
    1987 Antibodies directed at Fab of IgA in the sera of normal individuals and IgA nephropathy patients. 1987
    1987 Complement activation in IgA nephropathy 1987
    1987 Complement phenotypes (C3 and C4) in IgA nephropathy. 1987
    1987 Detection of food antigen-specific IgA immune complexes in human sera. 1987
    1987 Fatal rhizopus infections in hemodialysis patients receiving deferoxamine 1987
    1987 IgA-associated renal diseases: immunochemical studies of IgA1 proteins, circulating immune complexes, and cellular interactions. 1987
    1987 Immunogenetic markers as prognostic features in patients from Kentucky with IgA nephropathy. 1987
    1987 Immunological studies of IgA nephropathy: familial and racial aspects. 1987
    1987 Influence of race on renal allograft survival in the pre- and postcyclosporine era. 1987
    1987 Oxalosis in Bone Causing a Radiographical Mimicry of Renal Osteodystrophy 1987
    1987 Regionalization in hereditary IgA nephropathy 1987
    1987 Striking Elevation of Serum IgA, IgA-Containing Immune Complexes, and IgA Rheumatoid Factor in Clinically Silent Dermatitis Herpetiformis 1987
    1986 Aluminum-associated renal osteodystrophy. 1986
    1986 Aluminum-related bone disease in mild and advanced renal failure: Evidence for high prevalence and morbidity and studies on etiology and diagnosis 1986
    1986 Circulating immune complexes and immunoglobulin A rheumatoid factor in patients with mesangial immunoglobulin A nephropathies 1986
    1986 IgA-associated renal diseases: Antibodies to environmental antigens in sera and deposition of immunoglobulins and antigens in glomeruli 1986
    1985 Familial IgA Nephropathy 1985
    1985 Familial IgA Nephropathy: Evidence of an Inherited Mechanism of Disease 1985
    1985 Focal Sclerosis of Hypertrophied Glomeruli in Solitary Functioning Kidneys of Humans 1985
    1985 The immunogenetics of IgA nephropathy 1985
    1984 Complement phenotypes in glomerulonephritis: Increased frequency of homozygous null C4 phenotypes in IgA nephropathy and Henoch-Schonlein purpura 1984
    1984 IgA Nephropathy: Presentation, Clinical Course, and Prognosis in Children and Adults 1984
    1984 Increased frequency of C3 fast alleles in IgA nephropathy 1984
    1983 Serum complement proteins in IgA nephropathy 1983
    1982 Partial H (β1H) deficiency and glomerulonephritis in two families 1982
    1982 Renin and aldosterone responses to short-term NaCl or NaHCO3 loading in man 1982
    1981 Properdin Deficiency with IgA Nephropathy 1981

    Chapter

    Year Title Altmetric
    2016 Heterogeneity of aberrant O-glycosylation of IgA1 in IgA nephropathy.  53-68. 2016
    2015 IgA Nephropathy and Related Diseases.  2023-2038. 2015
    2009 Clinicopathologic findings.  83-106. 2009

    Research Overview

  • IgA nephropathy
    Kidney transplantation

    • Principal Investigator On

    Investigator On

  • Private Grant  awarded by CALLIDITAS THERAPEUTICS AB 2019 - 2026
  • Pathogenic Autoantibodies with Specificity for Aberrant Glycoproteins: Assessment of a Therapeutic Target in an Autoimmune Disease  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2020 - 2025
  • Molecular Basis of Pathogenicity of IgA1-Containing Immune Complexes  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2019 - 2024
  • Private Grant  awarded by RETROPHIN, INC. 2019 - 2024
  • Private Grant  awarded by VELOXIS PHARMACEUTICALS A/S 2019 - 2023
  • Private Grant  awarded by CSL BEHRING, LLC 2017 - 2022
  • Private Grant  awarded by MALLINCKRODT, INC. 2017 - 2022
  • Private Grant  awarded by ALEXION PHARMACEUTICALS, INC. 2018 - 2020
  • Effects of Inhibiting Early Inflammation in Kidney Transplant Patients  awarded by ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 2019 - 2020
  • Abnormal STAT3 Signaling and Aberrant O-Glycosylation of IgA1 in IgA Nephropathy  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2015 - 2020
  • Novel Therapies to Modulate the Inflammatory Alloresponse in Renal Grafts  awarded by University of California, San Francisco 2019 - 2020
  • Elucidating IgA Nephropathy Through Genetic Studies of IgA1 Glycosylation  awarded by Columbia University 2014 - 2020
  • Analytical Tools for the Analysis of Clustered O-Glycans in Clinical Samples  awarded by National Institute of General Medical Sciences/NIH/DHHS 2016 - 2020
  • Genetics of IgA Nephropathy by Integrative Network-Based Association Studies  awarded by Columbia University 2015 - 2020
  • Genetic, Environmental & Histologic Basis for Kidney Disease Risk among Persons Living with HIV  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2018 - 2019
  • Effects of Inhibiting Early Inflammation in Kidney Transplant Patients - Equipment  awarded by Mount Sinai School of Medicine 2015 - 2019
  • Novel Therapies to Modulate the Inflammatory Alloresponse in Renal Grafts  awarded by University of California, San Francisco 2014 - 2019
  • APOL1 Long-Term Kidney Transplantation Outcomes Network (APOLLO) Clinical Center  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2019
  • UAB Center for AIDS Research  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2014 - 2019
  • Private Grant  awarded by QUARK PHARMACEUTICALS, INC. 2015 - 2019
  • Molecular Basis of Pathogenicity of IgA1-containing Immune Complexes  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2012 - 2019
  • Aptamers-Based Arrays for Detection of Pathogenic IgA 1 O-Glycoforms in IgA Nephropathy  awarded by Columbia University 2016 - 2018
  • IgA Nephropathy: Interventions with Generation of Nephritogenic Immune Complexes  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2014 - 2018
  • Private Grant  awarded by ALEXION PHARMACEUTICALS, INC. 2014 - 2017
  • Preserving Renal Function & Protective Immunity via Anti-LFA-1-Based CNI Avoidance  awarded by Emory University 2009 - 2016
  • Analytical Tools for the Analysis of Clustered O-Glycans in Clinical Samples  awarded by National Institute of General Medical Sciences/NIH/DHHS 2011 - 2016
  • Private Grant  awarded by ANTHERA PHARMACEUTICALS, INC 2015 - 2016
  • Private Grant  awarded by Pfizer Pharmaceuticals 2013 - 2015
  • Elucidating IgA Nephropathy Through Genetic Studies of IgA1 Glycosylation  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2009 - 2014
  • New Animal Model for Studies of Mucosal Immunity and IgA Nephropathy  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2010 - 2013

    • Education And Training

  • Doctor of Medicine, Washington University/St. Louis 1975
  • University of Kentucky/Chandler Hospital, Internship 1976
  • University of Kentucky/Chandler Hospital, Residency 1978
  • University of Kentucky/Chandler Hospital, Postdoctoral Fellowship 1980

    • Full Name

  • Bruce Julian